Sarepta Therapeutics Stock Current Valuation
| S1RP34 Stock | BRL 21.08 1.64 7.22% |
Valuation analysis of Sarepta Therapeutics helps investors to measure Sarepta Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Fairly Valued
Today
Please note that Sarepta Therapeutics' price fluctuation is not too volatile at this time. Calculation of the real value of Sarepta Therapeutics is based on 3 months time horizon. Increasing Sarepta Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Sarepta Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Sarepta Stock. However, Sarepta Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 21.08 | Real 20.24 | Hype 21.08 | Naive 17.31 |
The real value of Sarepta Stock, also known as its intrinsic value, is the underlying worth of Sarepta Therapeutics Company, which is reflected in its stock price. It is based on Sarepta Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Sarepta Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Sarepta Therapeutics helps investors to forecast how Sarepta stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Sarepta Therapeutics more accurately as focusing exclusively on Sarepta Therapeutics' fundamentals will not take into account other important factors: Sarepta Therapeutics Company Current Valuation Analysis
Sarepta Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Sarepta Therapeutics Current Valuation | 56.41 B |
Most of Sarepta Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sarepta Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Sarepta Therapeutics has a Current Valuation of 56.41 B. This is 292.71% higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The current valuation for all Brazil stocks is significantly lower than that of the firm.
Sarepta Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sarepta Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sarepta Therapeutics could also be used in its relative valuation, which is a method of valuing Sarepta Therapeutics by comparing valuation metrics of similar companies.Sarepta Therapeutics is currently under evaluation in current valuation category among its peers.
Sarepta Fundamentals
| Return On Equity | -1.59 | |||
| Return On Asset | -0.11 | |||
| Profit Margin | (0.82) % | |||
| Operating Margin | (0.61) % | |||
| Current Valuation | 56.41 B | |||
| Shares Outstanding | 1.76 B | |||
| Price To Book | 25.76 X | |||
| Price To Sales | 67.46 X | |||
| Revenue | 701.89 M | |||
| Gross Profit | (165.84 M) | |||
| EBITDA | (317.41 M) | |||
| Net Income | (418.78 M) | |||
| Cash And Equivalents | 1.74 B | |||
| Cash Per Share | 21.78 X | |||
| Total Debt | 1.1 B | |||
| Debt To Equity | 2.19 % | |||
| Current Ratio | 6.23 X | |||
| Book Value Per Share | 4.91 X | |||
| Cash Flow From Operations | (443.17 M) | |||
| Earnings Per Share | (22.24) X | |||
| Number Of Employees | 840 | |||
| Beta | 0.97 | |||
| Market Capitalization | 58.46 B | |||
| Total Asset | 3.15 B | |||
| Z Score | 31.8 | |||
| Net Asset | 3.15 B |
About Sarepta Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sarepta Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sarepta Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sarepta Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Information and Resources on Investing in Sarepta Stock
When determining whether Sarepta Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Sarepta Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Sarepta Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Sarepta Therapeutics Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sarepta Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Sarepta Stock refer to our How to Trade Sarepta Stock guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.